Effect of Combining Liraglutide with the “5:2” Intermittent Fasting Diet on Weight and Body Composition in Participants Discontinuing Weekly Weight-Loss Therapeutics (LIFE)

开始日期2026-05-20

申办/合作机构

南京鼓楼医院

NCT07301437

/ Not yet recruiting临床4期IIT

A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

开始日期2026-05-01

申办/合作机构-

100 项与利拉鲁肽相关的临床结果

登录后查看更多信息

100 项与利拉鲁肽相关的转化医学

登录后查看更多信息

100 项与利拉鲁肽相关的专利（医药）

登录后查看更多信息

3,265

项与利拉鲁肽相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers

Review

作者: Chikatimalla, Rahul ; Aggarwal, Kanishk ; Shah, Twinkle ; Perry, Griffin ; Shah, Ashka ; Banker, Himanshi ; Jain, Rohit

OBJECTIVES:

To evaluate the current evidence supporting the cerebrovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM), and to outline their mechanisms of action in stroke prevention.

METHODS:

A narrative review was conducted by synthesising data from cardiovascular outcome trials, meta-analyses and mechanistic studies involving GLP-1RAs such as semaglutide, liraglutide and dulaglutide. The search included literature on ischaemic stroke incidence, molecular pathways and clinical outcomes associated with GLP-1RA therapy.

RESULTS:

GLP-1RAs exhibit multiple protective mechanisms, including anti-inflammatory, antioxidant, neuroprotective and endothelial-stabilising effects. Long-acting agents demonstrate superior efficacy in reducing nonfatal and ischaemic stroke risk, with relative risk reductions ranging from 15% to 39% across major trials. These benefits are observed independent of glycemic control and appear most prominent in patients with preserved renal function and shorter diabetes duration. In contrast, short-acting exendin-based GLP-1RAs show limited cerebrovascular benefit. Treatment response may vary based on factors such as stroke subtype, baseline vascular risk and comorbidities.

CONCLUSION:

GLP-1RAs offer significant promise as adjunctive pharmacotherapy for stroke prevention in individuals with T2DM. Their multifactorial benefits extend beyond glucose regulation and may influence clinical outcomes through systemic vascular and neuroprotective mechanisms. However, inconsistencies in trial outcomes and limited data in non-diabetic or high-risk populations underscore the need for targeted stroke-specific studies. Personalised treatment approaches and broader risk stratification may optimise their use in cerebrovascular disease management.

2026-12-01·JOURNAL OF MOLECULAR HISTOLOGY

Liraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation

Article

作者: Zhang, Nan ; Zhang, Jie ; Chen, Yiqing ; Zhou, Weifeng ; Wang, Ping

Obesity-related type 2 diabetes mellitus (O&T2DM) has become a major global public health issue. Chronic low-grade inflammation in adipose tissue is one of its core pathological features, among which excessive infiltration of M1-type macrophages and impaired function of M2-type macrophages are key drivers of inflammation. Liraglutide, a glucagon-like peptide-1 receptor agonist, exhibits significant glucose-lowering, weight-reducing, and anti-inflammatory effects. However, the molecular mechanisms by which liraglutide regulates cholesterol metabolism and epigenetic modifications in adipose tissue macrophages remain to be fully elucidated. A high-fat diet combined with streptozotocin was used to establish an O&T2DM model in male C57BL/6 mice. After 8 weeks of intervention, metabolic phenotypes, adipose tissue macrophage polarization, and cholesterol metabolism-related indicators were assessed. Raw264.7 macrophages were cultured in vitro and stimulated with IFN-γ + LPS to induce M1 polarization. Following liraglutide pretreatment, cell polarization phenotypes, the expression of genes involved in cholesterol metabolic pathways, and histone modification levels were examined. Using shRNA gene silencing, p300 inhibitor intervention, and Acetyl-CoA supplementation experiments in combination with ChIP-qPCR, the central role of the cholesterol metabolism-epigenetic axis in macrophage polarization was elucidated. Finally, a Transwell co-culture system was employed to verify the regulatory effects of liraglutide-reprogrammed macrophages on adipocyte lipid accumulation and energy metabolism. Liraglutide significantly reduced body weight, fasting blood glucose, and HOMA-IR in O&T2DM mice, decreased visceral fat accumulation, and promoted adipose tissue browning. It also increased the proportion of M2 macrophages within adipose tissue and significantly activated the key cholesterol efflux pathway LXRα/ABCA1. In vitro experiments confirmed that liraglutide pretreatment suppressed IFN-γ + LPS-induced M1 polarization and promoted the expression of M2-type markers, upregulated the expression of ABCA1, ABCG1, PPARγ, and LXRα, and increased levels of histone H3K27ac. Mechanistic studies revealed that silencing ABCA1 or LXRα reversed the liraglutide-induced increase in H3K27ac and M2 polarization. Acetyl-CoA supplementation partially restored the macrophage polarization phenotype following ABCA1 silencing. ChIP-qPCR results showed that liraglutide significantly enhanced the enrichment of H3K27ac in the promoter regions of M2 polarization genes and cholesterol metabolism genes. Co-culture experiments demonstrated that liraglutide-reprogrammed macrophages significantly promoted adipocyte thermogenic gene expression, increased mitochondrial membrane potential-dependent staining intensity, and enhanced ATPase activity via paracrine signaling, an effect that was blocked by silencing ABCA1 or LXRα. This study demonstrates that liraglutide activates the ABCA1/LXRα-mediated cholesterol metabolism pathway, upregulates histone H3K27ac modification, and drives macrophage M2 polarization, which in turn induces adipocyte lipid accumulation and mitochondrial metabolic activation via paracrine signaling. These findings provide a new molecular mechanism for the anti-inflammatory and metabolic-improving effects of liraglutide, and also offers a potential epigenetic target for the treatment of O&T2DM.

2026-12-01·Current Opinion in Endocrinology Diabetes and Obesity

Urological manifestations in obesity

Review

作者: Jayapal, Badhrinath ; Kapoor, Nitin

Purpose of review:

The global prevalence of obesity continues to rise, with effects ranging across urology. This review summarizes recent evidence on obesity and its impact on various urological conditions, including malignancy, infections, stone disease, functional urology and male reproductive health, chronic kidney disease, and pediatric urology, to guide comprehensive management in this population.

Recent findings:

Obesity has a paradoxical survival benefit in patients with renal cell carcinoma, while its impact drives aggressive prostate cancer. Obesity increases kidney stone risk, with sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists showing divergent effects on lithogenesis and urinary tract infections. It is a modifiable risk factor for overactive bladder and stress urinary incontinence, both of which improve with weight loss/ bariatric surgery. Robotic surgery mitigates obesity-related perioperative risk. Hypogonadism secondary to obesity is a major reversible cause of male infertility. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reverse metabolic hypogonadism and helps in slowing chronic kidney progression. Maternal and childhood obesity may impair testicular descent and can also increase the risk of nocturnal enuresis.

Summary:

Obesity's urological effects are heterogeneous, paradoxical from pediatric to adults, mediated by insulin resistance, chronic inflammation, and hormonal dysregulation. Weight loss and the use of GLP-1 RA may offer a unique strategy for optimizing and treating urological conditions.

2,273

项与利拉鲁肽相关的新闻（医药）

2026-11-03

·BioSpace

BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week

Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival PARIS--(BUSINESS WIRE)-- BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT , at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inventor Dr. Farid Bennis, the technology uses a dissolvable effervescent tablet to create a buffered solution that helps protect peptides during gastrointestinal transit and support systemic delivery. "The rapid evolution of peptide medicines continues to create opportunities for innovation in drug delivery," said Dr. Farid Bennis, Founder of BioLife. "Our work reflects many years of research into the challenges of oral peptide delivery. London Life Sciences Week provides an important opportunity to share our progress and explore the potential of this approach with those advancing the next generation of peptide therapeutics." Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration, providing in vivo proof of concept. Combined with earlier human clinical research involving oral insulin formulations, these findings provide a scientific foundation for further investigation across additional peptide medicines, subject to further validation. BioLife's technology is supported by granted patents in the United States and France, with additional international filings progressing. Its U.S. patent includes claims covering multiple GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide, with protection extending into 2042. About the Technology BioLife's patented effervescent peptide delivery technology uses a dissolvable tablet to create a buffered solution designed to help protect peptide medicines during gastrointestinal transit and support systemic delivery. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration. The development programme builds on nearly 20 years of research, including human clinical studies with oral insulin formulations and work with Charles River Laboratories, SGS, Eurofins/Amatsi and Cephac. The technology is in development and is not approved for the treatment of any disease. About BioLife BioLife develops oral delivery technologies for peptide medicines, combining expertise in pharmaceutical effervescence, formulation science and oral peptide research. The company's technology portfolio and related patent estate have been independently developed and are wholly owned. Website: Contacts For Enquiries Contact James P. Cain U.S. Ambassador (Ret.) Strategic Advisor to the Chairman & Founder BioLife Products Limited jpc@biolife.bio Ludivine Delattre Business and Corporate Relations BioLife Products Limited ld@biolife.bio

多肽偶联药物

2026-11-02

·米内网

83个国谈药，卖爆了

精彩内容米内网数据显示，2026H1中国公立医疗机构终端（统计范围详见本文末）83个国谈药销售额突破3亿元，合计接近640亿元；独家品种占比接近90%，10余家企业有2个及以上的品种在列，恒瑞以8个品种领跑。蓄力期：首批国谈品种在列，5个中成药亮眼 20世纪初到2017年，国内医药产业以原料药、仿制药、中成药为主，创新药尚处于起步蓄力阶段，真正意义上的全球首创药物几乎空白。 2018年之前（不含2018年）获批上市的国谈品种（2025版，下同）中，有18个2026H1销售额超过3亿元，以血液和造血系统药物、抗肿瘤和免疫调节剂为主，石药、丽珠、贝达等走在前列。 2018年之前获批的部分国谈药注：标*为销售额增速低于5% 醋酸戈舍瑞林缓释植入剂（阿斯利康）、丁苯酞氯化钠注射液（石药）、重组人血小板生成素注射液（三生制药）2026H1销售额均达20亿元以上，西妥昔单抗注射液（默克）超过12亿元；仅4个品种（占比约22%）同比有双位数增长，长春金赛的金培生长激素注射液涨逾40%，石药集团的注射用重组人TNK组织型纤溶酶原激活剂涨逾30%等。 5个中成药在列，分别为丹红注射液（步长）、康莱特注射液（康莱特）、蓝芩口服液（扬子江）、血必净注射液（红日药业）、注射用丹参多酚酸盐（绿谷制药），涉及心脑血管、呼吸、肿瘤等治疗领域，其中注射用丹参多酚酸盐同比有超10%的涨幅。 3个品种拥有国谈药、国家基药“双身份”，石药的丁苯酞氯化钠注射液、丁苯酞软胶囊均为2026版基药新增品种；盐酸埃克替尼片（原研贝达+1家仿制）为2016年首批国谈品种之一。喷发期：单抗、TKI发力，恒瑞领跑 2018年开始，国内创新药步入高速发展阶段。国家医保局挂牌，三医联动步入新阶段；“4+7”集采试点启动，仿制药利润空间被压缩；港股18A规则落地，催生一批Biotech公司上市；药品审评审批制度改革，创新药上市速度加快；大规模国谈启动，同步建立“调出机制”等。在2018-2020年间获批上市的国谈品种中，有31个2026H1销售额超过3亿元，抗肿瘤和免疫调节剂以绝对的优势领跑，单抗类、小分子靶向药蓬勃发展；独家品种占比约84%，恒瑞以4个品种领跑，翰森、百济神州、吉利德等均有2个品种在列。 2018-2020年获批的部分国谈药注：标*为销售额增速低于5% 替雷利珠单抗注射液（百济神州）、信迪利单抗注射液（信达）2026H1销售额均达20亿元以上，盐酸安罗替尼胶囊（正大天晴）、甲磺酸阿美替尼片（翰森制药）、依达拉奉右莰醇注射用浓溶液（原研先声+4家仿制）、依洛尤单抗注射液（安进）、特瑞普利单抗注射液（君实）、司库奇尤单抗注射液（诺华）超过10亿元。 18个品种（占比约58%）同比有双位数增长。其中，江苏杜瑞制药的首仿品种注射用甲磺酸萘莫司他涨逾80%，非独家品种奈妥匹坦帕洛诺司琼胶囊涨逾50%，特瑞普利单抗注射液、氟替美维吸入粉雾剂、环硅酸锆钠散涨逾30%等。君实生物、信达生物、恒瑞医药、百济神州有国产PD-1四小龙之称。君实生物的特瑞普利单抗注射液是国内获批的首个国产PD-1单抗，近年来稳扎稳打；百济神州的替雷利珠单抗注射液虽然获批时间较晚，但商业化表现出色，销售额已超过其他几款国产PD-1单抗。近年来中国公立医疗机构终端部分国产PD-1销售情况（单位：万元）高质量期：双抗、ADC、皮下给药崭露头角 2021年开始，以临床价值为导向的研发策略被提上日程，创新药由“数量扩张”转向“高质量创新”。审评审批效率进一步提升，医保、商保支付机制更加完善，国产创新药对外授权交易增加等。 2021年及之后获批上市的国谈品种中，有35个2026H1销售额超过3亿元，抗肿瘤和免疫调节剂仍以绝对的优势领跑，双抗药物、ADC、皮下给药方式崭露头角；独家品种占比约91%，恒瑞、罗氏以4个品种领跑，诺华有3个品种在列，康方、荣昌、诺和诺德等有2个品种在列。 2021年至今获批的部分国谈药注：标*为销售额增速低于5% 司美格鲁肽注射液（诺和诺德）以超26亿元领跑，甲磺酸伏美替尼片（艾力斯）、帕妥珠曲妥珠单抗注射液(皮下注射)（罗氏）均超过10亿元，德谷胰岛素利拉鲁肽注射液（诺和诺德）接近10亿元。 30个品种（占比约88%）同比有双位数及以上增长，其中有10个涨逾110%。托莱西单抗注射液（信达）以约852%的增速领跑，英克司兰钠注射液（诺华）以约550%的增速紧接在后。 3款ADC亮眼，分别为靶向HER2的注射用德曲妥珠单抗（第一三共，2023年）、注射用维迪西妥单抗（荣昌生物，2021年），以及靶向CD79b的注射用维泊妥珠单抗（罗氏，2023年）。近年来中国公立医疗机构终端部分ADC销售情况（单位：万元） 4款双抗药物在列（不含融合蛋白），分别为罗氏的帕妥珠曲妥珠单抗注射液(皮下注射)（HER2双表位）及法瑞西单抗注射液（VEGF-A/Ang-2），均最早于2023年底获批；康方的依沃西单抗注射液（PD-1/VEGF-A）及卡度尼利单抗注射液（PD-1/CTLA-4），其中依沃西单抗最早于2024年5月获批。近年来中国公立医疗机构终端部分双抗销售情况（单位：万元）资料来源：米内网数据库等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。

上市批准免疫疗法核酸药物

2026-11-02

·腾讯自选股

超4成医药生物公司前三季度业绩增长

记者｜季媛媛编辑｜包芳鸣截至10月底，A股与港股创新药企2026年三季报密集披露。已披露企业中，超四成医药生物公司前三季度业绩同比增长。驱动业绩的已不是单一变量。一边是创新药国内商业化真正跑通，另一边是BD（商务拓展）从“战略故事”变成“利润科目”，首付款、里程碑收入直接进表。有券商分析师对21世纪经济报道记者表示，这意味着，中国创新药企的估值锚正在重构。过去市场只看“管线条数、临床阶段”，现在必须同时看“两个现金流”：一个是产品卖货带来的可持续经营现金流，一个是BD带来的全球化资产变现现金流。前者决定下限，后者打开上限。商业化底盘如果说BD是2026年三季报最抢眼的“利润放大器”，那商业化能力就是被BD光环掩盖、却决定企业生死的“底盘工程”。创新药行业过去十年反复上演“获批即巅峰、进院即滑坡”，核心痛点在于好药做出来，却进不了科室、盖不过竞品、算不回投入。今年三季报，头部企业给出的信号是：商业化正从“销售费用比拼”升级为“准入+适应症+渠道”的系统能力。恒瑞医药是最典型的样本。前三季度，公司创新药销售收入138.71亿元，同比增长17.05%，占药品销售收入的比重提升至64.59%，收入结构持续优化。其中，抗肿瘤创新产品收入98.65亿元，同比增长3.13%，占整体创新药销售收入的71.12%；非肿瘤创新产品收入40.06亿元，同比增长75.36%，占整体创新药销售收入的28.88%。海思科则验证了“单品深耕”的路径。公开信息显示，公司已拥有五款获批上市的1类创新药，其中，环泊酚注射液2026年5月获美国FDA批准上市，成为中国首个走向国际的静脉麻醉原研创新药，在静脉麻醉药领域市场份额位居前列。诺诚健华的商业化曲线同样清晰。奥布替尼持续放量，坦昔妥单抗、佐来曲妥单抗新增贡献，前三季度药品销售收入14.5亿元，同比增长41.5%，经营现金流达2.2亿元，同比转正。对Biotech而言，“现金流靠销售转正”比“利润表扭亏”更重要——它意味着不再依赖融资输血。诺诚健华首席财务官傅欣在业绩交流会上表示，2026年前三季度，公司保持了良好的盈利态势，实现净利润6.48亿元人民币，而2025年同期为亏损7200万元。基于前三季度的业绩表现，预计2026年全年仍将持续盈利并且每股收益高于上半年的水平。君实生物、三生国健、翰宇药业则分别代表三类商业化形态：君实靠特瑞普利单抗实现国内+出海双线发力；三生国健靠自免管线（益赛普等）实现稳态销售+授权协同；翰宇药业前三季度营收同比增长81.87%，归母净利润4.37亿元（同比增长约5.12倍），扣非净利4.28亿元，同比增长741.83%，增长主要由多肽原料药放量驱动。但繁荣之下仍需冷静审视。前述分析师进一步指出，一方面，多数企业存在单品依赖，TOP1品种贡献超五成收入，适应症天花板临近时增速会陡降。例如，翰宇药业以GLP-1相关多肽（利拉鲁肽、司美格鲁肽、替尔泊肽等）切入海外客户供应链，带动原料药收入占比升至近八成，但业绩对GLP-1订单节奏依赖度较高；另一方面，国内医保控费、集采外溢、同质化竞争也未消失。此外，院端准入区域不平衡，三四线城市与基层市场渗透仍慢，真实世界处方转化滞后于获批进度。所以三季报看到的“商业化向好”，本质是头部企业过了“从0到1”的进院关，但还没完全过“从1到N”的精细化运营关。下一步比拼的是：适应症组合、真实世界证据、零售与线上处方、基层市场下沉，以及海外自主商业化能力。“没有这套体系，BD再大，也只是把未来收益提前贴现，不能替代主业造血。”上述分析师说。BD兑现期2026年三季报另一个标志性变化，是BD收入从“偶尔惊喜”变成“可预测科目”。恒瑞是“BD常态化”的代表。前三季度，公司创新药对外许可业务确认收入27.81亿元，同比增长31.12%，主要为GSK及BMS根据履约义务的完成进度确认的收入以及个别已授权产品的里程碑款等收入。公司收到对外许可合作首付款及里程碑款现金共43.43亿元，主要为BMS的6亿美元首付款。9月29日，恒瑞与诺和诺德就GLP-1/GIP双受体激动剂HRS-1596达成许可协议。根据协议条款，诺和诺德将获得在大中华区以外的全球范围内开发、生产和商业化HRS-1596的独家权利。该交易潜在总交易额最高可达26亿美元，预计于2026年第四季度完成交割。海思科是“高频授权+分层出海”的样本。2026年内连续与AirNexis、AbbVie、礼来、Nuvectis、Sentivera达成合作，五笔交易潜在总金额超77亿美元（均为里程碑上限，非当期现金流入）。其BD逻辑不是押注单管线，而是按资产成熟度分层释放价值：后期分子授权给MNC、早期资产装入NewCo拿股权、研发能力输出给礼来，降低单点失败风险，把“持续造分子的能力”而非单个产品，作为全球化定价的锚。诺诚健华前三季度实现BD收入6.5亿元，主要为与Zenas合作确认的各项里程碑收入。此外，2026年第三季度，诺诚健华与礼来达成研发及授权许可战略合作，交易总金额最高达33.5亿美元。实际上，这种变化的深层意义，是行业定价权上移。有药企高管对21世纪经济报道记者表示，过去中国药企BD常被视作“早期青苗折价出售”，如今跨国MNC愿意付大额首付款、让渡共同开发权、接受销售分成，说明中国管线的价值来源已从“低成本临床”转向“早期科学原创+高效转化”。Co-Co（共同开发）模式普及，让本土企业从“配角供应商”变成“联合农场主”。但必须拆穿一层滤镜：BD总额不等于到账收入。有创新药企高管对21世纪经济报道记者表示，潜在总额里的里程碑款，依赖后续临床、注册、销售节点触发。行业统计显示，生物制药BD交易中超六成里程碑最终未全额达成。三季报里一次性首付款推高的净利润，会在未来某个季度回归常态。若市场把“BD预期”提前透支进估值，一旦某笔关键临床数据不及预期，回撤会非常剧烈。科律律师事务所（Cooley）上海办事处主管合伙人刘毅铭律师日前也对21世纪经济报道记者表示，管线退货、提前终止等条款，是当前BD协议谈判中受到高度重视和考量的内容。创新药企必须在合作蜜月期就设计好体面分手的防御机制。“在合同起草阶段，有很多方面可以设置机制，例如约定合作方在开发和商业化工作中尽量具体明确的勤勉义务，又例如明确合作终止后的反向授权与数据回流等机制，确保管线可以持续推进或进一步寻求合作等。”这也意味着，对创新药BD的解读要分三层：首付款看当下现金流，里程碑看执行能力，销售分成看长期资产质量。真正健康的药企，应构建“BD反哺研发、研发产出新BD”的飞轮，而不是陷入“签大单救报表”的脉冲。而2026年三季度，是本土创新药企的“兑现时刻”，也是“分层起点”。谁能在BD热潮里守住研发定力，谁能在商业化红海中做出壁垒，谁就能走向“全球定价”。SFC出品丨21财经客户端 21世纪经济报道编辑丨林芊蔚

财报上市批准引进/卖出

100 项与利拉鲁肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06404	利拉鲁肽	A10BJ02	DB06655

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Novo Nordisk, Inc.	2014-12-23
超重	美国	Novo Nordisk, Inc.	2014-12-23
2型糖尿病	欧盟	Novo Nordisk A/S	2009-06-30
2型糖尿病	冰岛	Novo Nordisk A/S	2009-06-30
2型糖尿病	列支敦士登	Novo Nordisk A/S	2009-06-30
2型糖尿病	挪威	Novo Nordisk A/S	2009-06-30
2型糖尿病	英国	Novo Nordisk Ltd.	2009-06-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑血管疾病	临床3期	德国	Novo Nordisk A/S	2020-11-01
慢性心力衰竭	临床3期	德国	Novo Nordisk A/S	2020-11-01
冠状动脉疾病	临床3期	德国	Novo Nordisk A/S	2020-11-01
外周血管疾病	临床3期	德国	Novo Nordisk A/S	2020-11-01
多内分泌代谢卵巢综合征	临床3期	美国	Novo Nordisk A/S	2018-09-26
暴食症	临床3期	美国	Novo Nordisk A/S	2017-09-29
普拉德-威利综合症	临床3期	美国	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	澳大利亚	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	加拿大	Novo Nordisk A/S	2015-11-09
普拉德-威利综合症	临床3期	法国	Novo Nordisk A/S	2015-11-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


LIGHT-MCI (EASD2026)	临床3期	2型糖尿病	396	MetforminLiraglutide + MetforminLiraglutide	艱鹽網餘衊壓夢構廠範(淵製衊鏇憲積願齋窪鹽) = 醖膚簾淵壓範餘製齋觸鏇築夢壓膚範鬱鹽遞鬱 (積襯糧齋繭網淵窪獵積 )	积极	2026-09-28
				EmpagliflozinMetforminozin + EmpagliflozinMetformin	艱鹽網餘衊壓夢構廠範(淵製衊鏇憲積願齋窪鹽) = 憲醖蓋餘鹽獵鹽艱選積鏇築夢壓膚範鬱鹽遞鬱 (積襯糧齋繭網淵窪獵積 )
ESC2026	N/A	2型糖尿病	336	Insulin	構餘鹹醖遞膚淵鑰獵淵(鹽鏇選觸鏇廠鏇鏇壓簾) = 壓窪壓觸壓繭網餘願簾齋糧願積範觸襯繭鹹壓 (鹽顧醖齋夢築顧襯壓糧, 344 ~ 781)	积极	2026-08-30
				GLP1-RA	構餘鹹醖遞膚淵鑰獵淵(鹽鏇選觸鏇廠鏇鏇壓簾) = 鹽鬱築壓遞願窪鹹艱鑰齋糧願積範觸襯繭鹹壓 (鹽顧醖齋夢築顧襯壓糧, 36 ~ 396)
LIRA-HF (ESC2026)	临床3期	射血分数降低的心力衰竭	590	Liraglutide + Liraglutide	積壓齋窪遞鹹顧構簾選(廠鹽觸膚壓窪夢糧糧憲) = Liraglutide improved the primary outcome (Win Ratio 1.36; 95% CI 1.14-1.62; p<0.001). 襯糧艱蓋顧鹹鑰醖醖餘 (憲鬱鹽艱鏇糧選廠襯艱 ) 更多	积极	2026-08-29
				GDMT alone
ENDO2026	N/A	2型糖尿病	60,222	Liraglutide	範夢網鹹糧齋選繭簾繭(廠夢窪夢積製壓夢淵蓋): HR = 0.72 (95.0% CI, 0.69 ~ 0.76) 更多	积极	2026-06-14
				Semaglutide
DDW2026	N/A	溃疡性结肠炎	150	Liraglutide	構觸淵觸餘鹽製簾鹽鏇(網網襯選廠襯選艱壓簾) = 憲鑰簾鑰繭醖願餘壓繭鹽願餘範願窪網遞廠鹽 (蓋膚觸願醖製製簾遞鏇 ) 更多	积极	2026-05-02
				Semaglutide	糧廠鏇窪選廠鏇構廠壓(醖鬱願鬱選獵築膚顧願) = 淵鏇積襯網鑰齋醖壓憲繭選餘觸壓窪醖夢艱襯 (鹽壓遞襯醖齋鏇獵齋衊 )
NCT02944500 (Pubmed \| Metabolism)	临床2期	肥胖	20	Liraglutide 3 mg	觸醖鏇襯願範範窪繭夢(願蓋鑰糧積憲顧顧鏇鬱) = 壓憲鹹齋鏇網蓋鑰衊遞築鏇構繭觸顧選憲範衊 (餘艱餘遞觸選齋製選積 ) 更多	积极	2026-04-01
NCT01794143 (GRADE, CTgov)	临床3期	2型糖尿病	7,850	Glargine Insulin (Glargine Insulin U-100)	糧範鹹糧簾鹹網膚膚選(蓋積範襯鑰願蓋淵積餘) = 壓淵夢襯餘築獵膚獵積願觸鏇鏇範鏇願衊艱鹽 (淵鏇艱構構壓網淵觸膚, 鑰壓憲廠獵鹽簾淵簾艱 ~ 醖窪觸餘壓築蓋積鹹餘) 更多	-	2026-02-10
				Glimepiride (Glimepiride)	糧範鹹糧簾鹹網膚膚選(蓋積範襯鑰願蓋淵積餘) = 夢膚網鏇廠築壓鏇構淵願觸鏇鏇範鏇願衊艱鹽 (淵鏇艱構構壓網淵觸膚, 膚網構壓衊餘鏇醖鏇蓋 ~ 醖鑰襯構觸網選遞觸網) 更多
NCT04122716 (Pubmed \| Sports Med)	临床3期	肥胖	193	Liraglutide (Exercise)	蓋醖淵顧製繭築網廠膚(糧願憲鏇鹽顧鏇鏇壓衊) = 憲鏇積構蓋鹽膚齋鑰鏇膚獵構夢蓋鏇艱構遞範 (廠鑰壓窪願餘願衊齋選, 0.5 ~ 5.5)	积极	2026-01-24
				Liraglutide alone	衊憲廠構蓋餘廠觸鏇憲(願襯衊獵膚範淵顧襯膚) = 糧鬱蓋襯憲簾艱餘鬱蓋遞夢簾鏇獵觸蓋範築窪 (壓壓簾網衊鹹廠壓鏇艱 )
AASLD2025	N/A	代谢功能障碍相关脂肪性肝炎	5,092	Liraglutide	齋遞糧醖範願遞餘築壓(顧簾醖夢鏇積襯廠糧簾): HR = 1.19 (95.0% CI, 0.73 ~ 1.93), P-Value = 0.45 更多	积极	2025-11-07
				Semaglutide
NCT03948347 (LAMP, Pubmed \| JAMA Intern Med) 人工标引	临床3期	2型糖尿病 \| 短暂性脑缺血发作 \| 急性缺血性卒中	636	Liraglutide	淵艱積繭製遞鏇蓋膚繭(願衊鏇鏇鏇廠艱觸鹽糧) = 選構範壓獵餘簾繭獵鏇衊製糧鹽製範範襯廠蓋 (憲艱構鏇繭淵糧繭網廠 ) 更多	积极	2025-11-03
				Control	淵艱積繭製遞鏇蓋膚繭(願衊鏇鏇鏇廠艱觸鹽糧) = 膚獵壓積膚襯選範鹽製衊製糧鹽製範範襯廠蓋 (憲艱構鏇繭淵糧繭網廠 ) 更多